Article

Bausch & Lomb offers upgrades for Zyoptix and Millennium systems

Bausch & Lomb has upgraded its Zyoptix 100 laser system by enhancing the safety and accuracy of the unit by introducing iris-recognition technology. The company also introduced an Advanced Flow System for its Millennium microsurgical system.

Paris—Bausch & Lomb has upgraded its Zyoptix 100 laser system by enhancing the safety and accuracy of the unit by introducing iris-recognition technology. The company also introduced an Advanced Flow System for its Millennium microsurgical system.

The iris-recognition of the Zyoptix laser is a specially designed software that captures the image of each patient's eye, transforms the iris structures into a digital key, called Zy-ID, and stores the information along with other diagnostic data. This new feature ensures that the correct eye is treated and, in the case of disparity, will not allow the procedure to proceed.

Other features include a personalized treatment planner for best patient treatment options, based on the diagnostic information gathered, and a new 100Hz laser source, which means treatment times will be shortened in half.

The Advanced Flow System on the Millennium is designed to provide surgeons who prefer flow-based phacoemulsification techniques with the responsiveness they expect. The unit also provides the widest range of control of fluidics and ultrasound power available, the company reported.

Advantages of the system include significant reduction of post-occlusion surge; optimized chamber stability due to low-compliance tubing and patented traducer; easy adjustment to a surgeon's preferred operating technique; phaco energy that is delivered in energy-efficient bursts to minimize fragment chatter and to improve followability while reducing heat; and Dual Linear control of both power and aspiration.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.